Ligand Pharmaceuticals Incorporated Uncategorized Contracts & Agreements
74 Contracts & Agreements
- Agreement on the Acquisition of Stocks in Apeiron Biologics AG entered on July 8, 2024, between Ligand Pharmaceuticals Incorporated and the sellers (Filed With SEC on August 7, 2024)
- Amendment to 2022 Employee Inducement Plan (Filed With SEC on February 29, 2024)
- Tax Matters Agreement, dated as of November 1, 2022, by and among Ligand Pharmaceuticals Incorporated, OmniAb Operations, Inc. and OmniAb, Inc (Filed With SEC on November 4, 2022)
- Sublicense Agreement between the Company, Pharmacopeia, Inc. and Retrophin LLC dated as of February 16, 2012, as amended through Amendment No. 5 to Sublicense Agreement, dated... (Filed With SEC on February 28, 2022)
- Call Option Amendment Agreed, dated January 28, 2021, between the Registrant and Goldman Sachs & Co. LLC (Filed With SEC on February 24, 2021)
- Call Option Amendment Agreed, dated January 28, 2021, between the Registrant and Deutsche Bank AG, London Branch (Filed With SEC on February 24, 2021)
- Call Option Amendment Agreed, dated January 28, 2021, between the Registrant and Barclays Bank PLC (Filed With SEC on February 24, 2021)
- Description of Registered Securities (Filed With SEC on February 24, 2021)
- Contingent Value Rights Agreement between Ligand Pharmaceuticals Incorporated and Vaughn Smider, as Members Representative (regarding Taurus Biosciences, LLC acquisition), dated... (Filed With SEC on September 10, 2020)
- Call Option Amendment Agreed, dated April 6, 2020, between the Registrant and Goldman Sachs & Co. LLC (Filed With SEC on May 8, 2020)
- Call Option Amendment Agreed, dated April 6, 2020, between the Registrant and Deutsche Bank AG, London Branch (Filed With SEC on May 8, 2020)
- Call Option Amendment Agreed, dated April 6, 2020, between the Registrant and Barclays Bank PLC (Filed With SEC on May 8, 2020)
- Sublicense Agreement between the Company, Pharmacopeia, Inc. and Retrophin LLC dated as of February 16, 2012, as amended through Amendment No. 5 to Sublicense Agreement, dated... (Filed With SEC on February 27, 2020)
- Description of Registered Securities (Filed With SEC on February 27, 2020)
- Break Fee Agreement, dated August 9, 2018, by and between Vernalis plc and Ligand Holdings UK Ltd (Filed With SEC on August 9, 2018)
- Rule 2.7 Announcement issued by Ligand Holdings UK Ltd., dated August 9, 2018 (Filed With SEC on August 9, 2018)
- [Signature Page Follows] (Filed With SEC on May 22, 2018)
- Amendment No. 5 to Sublicense Agreement, dated March 20, 2018, among the Company, Pharmacopeia, LLC and Retrophin, Inc (Filed With SEC on May 9, 2018)
- Consent of Independent Registered Public Accounting Firm (Filed With SEC on March 22, 2016)
- AMENDMENT NO. 4 TO SUBLICENSE AGREEMENT (Filed With SEC on November 9, 2015)
- AMENDMENT OF TR BETA CONTINGENT VALUE RIGHTS AGREEMENT (Filed With SEC on May 22, 2014)
- AMENDMENT OF GENERAL CONTINGENT VALUE RIGHTS AGREEMENT (Filed With SEC on May 22, 2014)
- RECITALS: (Filed With SEC on November 8, 2013)
- FIRST AMENDMENT TO 2006 PREFERRED SHARES RIGHTS AGREEMENT June 19, 2013 (Filed With SEC on June 20, 2013)
- SUBLICENSE AGREEMENT (Filed With SEC on May 4, 2012)
- CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY... (Filed With SEC on March 3, 2011)
- CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY... (Filed With SEC on March 3, 2011)
- CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY... (Filed With SEC on March 3, 2011)
- CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY... (Filed With SEC on March 3, 2011)
- CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY... (Filed With SEC on March 3, 2011)
- CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY... (Filed With SEC on March 3, 2011)
- CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY... (Filed With SEC on March 3, 2011)
- CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY... (Filed With SEC on March 3, 2011)
- AMENDMENT OF GENERAL CONTINGENT VALUE RIGHTS AGREEMENT (Filed With SEC on January 31, 2011)
- CONTINGENT VALUE RIGHTS AGREEMENT (Filed With SEC on January 26, 2011)
- AMENDMENT (Filed With SEC on March 3, 2010)
- CONTINGENT VALUE RIGHTS AGREEMENT (Filed With SEC on January 28, 2010)
- CONTINGENT VALUE RIGHTS AGREEMENT (Filed With SEC on January 28, 2010)
- CONTINGENT VALUE RIGHTS AGREEMENT (Filed With SEC on January 28, 2010)
- CONTINGENT VALUE RIGHTS AGREEMENT (Filed With SEC on January 28, 2010)
